Aridis Pharmaceuticals Stock Analysis
| ARDS Stock | USD 0.0002 0 92.86% |
Aridis Pharmaceuticals holds a debt-to-equity ratio of -0.1833. Aridis Pharmaceuticals' financial risk is the risk to Aridis Pharmaceuticals stockholders that is caused by an increase in debt.
Given that Aridis Pharmaceuticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Aridis Pharmaceuticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Aridis Pharmaceuticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Aridis Pharmaceuticals is said to be less leveraged. If creditors hold a majority of Aridis Pharmaceuticals' assets, the Company is said to be highly leveraged.
Aridis Pharmaceuticals is overvalued with Real Value of 1.92E-4 and Hype Value of 1.98E-4. The main objective of Aridis Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Aridis Pharmaceuticals is worth, separate from its market price. There are two main types of Aridis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Aridis Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Aridis |
Aridis Pink Sheet Analysis Notes
About 32.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.15. Aridis Pharmaceuticals had not issued any dividends in recent years. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.The quote for Aridis Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Aridis Pharmaceuticals please contact Vu Truong at 408 385 1742 or go to https://www.aridispharma.com.Aridis Pharmaceuticals Investment Alerts
| Aridis Pharmaceuticals is way too risky over 90 days horizon | |
| Aridis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aridis Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Aridis Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.37 M) with loss before overhead, payroll, taxes, and interest of (22.61 M). | |
| Aridis Pharmaceuticals currently holds about 6.32 M in cash with (29.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders |
Aridis Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aridis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aridis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 16th of February 2026, Aridis Pharmaceuticals shows the Mean Deviation of 226.78, risk adjusted performance of 0.2855, and Downside Deviation of 90.42. Aridis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aridis Pharmaceuticals information ratio, as well as the relationship between the potential upside and kurtosis to decide if Aridis Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.0E-4 per share. As Aridis Pharmaceuticals appears to be a penny stock we also recommend to validate its total risk alpha numbers.Aridis Pharmaceuticals Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aridis Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aridis Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Aridis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aridis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aridis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aridis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hamilton John F over a year ago Exercise or conversion by Hamilton John F of 5000 shares of Aridis Pharmaceuticals subject to Rule 16b-3 |
Aridis Pharmaceuticals Outstanding Bonds
Aridis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aridis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aridis bonds can be classified according to their maturity, which is the date when Aridis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Aridis Pharmaceuticals Predictive Daily Indicators
Aridis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aridis Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.0714 | |||
| Day Median Price | 2.0E-4 | |||
| Day Typical Price | 2.0E-4 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0) |
Aridis Pharmaceuticals Forecast Models
Aridis Pharmaceuticals' time-series forecasting models are one of many Aridis Pharmaceuticals' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aridis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Aridis Pharmaceuticals Debt to Cash Allocation
Many companies such as Aridis Pharmaceuticals, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.Aridis Pharmaceuticals Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Aridis Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Aridis Pharmaceuticals, which in turn will lower the firm's financial flexibility.Aridis Pharmaceuticals Corporate Bonds Issued
About Aridis Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Aridis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aridis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Aridis Pharmaceuticals. By using and applying Aridis Pink Sheet analysis, traders can create a robust methodology for identifying Aridis entry and exit points for their positions.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Aridis Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Additional Tools for Aridis Pink Sheet Analysis
When running Aridis Pharmaceuticals' price analysis, check to measure Aridis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aridis Pharmaceuticals is operating at the current time. Most of Aridis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aridis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aridis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aridis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.